全文获取类型
收费全文 | 5762篇 |
免费 | 283篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 221篇 |
妇产科学 | 99篇 |
基础医学 | 649篇 |
口腔科学 | 149篇 |
临床医学 | 463篇 |
内科学 | 998篇 |
皮肤病学 | 83篇 |
神经病学 | 407篇 |
特种医学 | 200篇 |
外科学 | 682篇 |
综合类 | 74篇 |
一般理论 | 5篇 |
预防医学 | 274篇 |
眼科学 | 223篇 |
药学 | 683篇 |
1篇 | |
中国医学 | 77篇 |
肿瘤学 | 722篇 |
出版年
2024年 | 5篇 |
2023年 | 34篇 |
2022年 | 116篇 |
2021年 | 200篇 |
2020年 | 99篇 |
2019年 | 134篇 |
2018年 | 174篇 |
2017年 | 112篇 |
2016年 | 148篇 |
2015年 | 199篇 |
2014年 | 228篇 |
2013年 | 331篇 |
2012年 | 503篇 |
2011年 | 474篇 |
2010年 | 257篇 |
2009年 | 255篇 |
2008年 | 362篇 |
2007年 | 367篇 |
2006年 | 346篇 |
2005年 | 352篇 |
2004年 | 307篇 |
2003年 | 266篇 |
2002年 | 214篇 |
2001年 | 57篇 |
2000年 | 59篇 |
1999年 | 54篇 |
1998年 | 47篇 |
1997年 | 23篇 |
1996年 | 33篇 |
1995年 | 35篇 |
1994年 | 27篇 |
1993年 | 30篇 |
1992年 | 29篇 |
1991年 | 27篇 |
1990年 | 13篇 |
1989年 | 15篇 |
1988年 | 9篇 |
1987年 | 6篇 |
1986年 | 5篇 |
1985年 | 10篇 |
1984年 | 13篇 |
1983年 | 8篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1976年 | 4篇 |
1973年 | 3篇 |
1972年 | 3篇 |
1971年 | 5篇 |
排序方式: 共有6058条查询结果,搜索用时 15 毫秒
51.
The p21-activated kinases signal through a number of cellular pathways fundamental to growth, differentiation and apoptosis.
A wealth of information has accumulated at an impressive pace in the recent past, both with regard to previously identified
targets for p21-activated kinases that regulate the actin cytoskeleton and cellular stress pathways and with regard to newly
identified targets and their role in cancer. Emerging data also provide new clues towards a previously unappreciated link
between these various cellular processes. The present review attempts to provide a quick tutorial to the reader about the
evolving significance of p21-activated kinases and small GTPases in breast cancer, using information from mouse models, tissue
culture studies, and human materials. 相似文献
52.
Martin A. Graham Suresh Senan Hernani Robin Jr. Nils Eckhardt Dennis Lendrem Jeffery Hincks Dennis Greenslade Roy Rampling Stanley B. Kaye Reinhard von Roemeling Paul Workman 《Cancer chemotherapy and pharmacology》1997,40(1):1-10
Tirapazamine (3-amino-1,2,4-benzotriazine-1,4-di-N-oxide; SR 259075) is a selective hypoxic cell cytotoxic agent that is bioreductively activated in tumours to a reactive-drug
free radical. Preclinically the agent has been shown to possess additive and synergistic anti-tumour activity in combination
with radiotherapy and chemotherapy regimens. In the present study the pharmacokinetics and metabolism of tirapazamine were
investigated in mice and patients as part of pre-clinical and phase I investigations. The objectives of this work were twofold;
firstly, to evaluate retrospectively the utility of a pharmacokinetically guided dose-escalation (PGDE) strategy for tirapazamine,
and secondly, to investigate if pharmacologically relevant plasma concentrations could be achieved at tolerable doses. Pharmacokinetic
studies for PGDE were conducted in mice at four dose levels ranging from one-tenth of the LD10 to the LD50. The AUC at the LD10 (2932 μg ml-1min) was used to determine a target AUC value of 1173 μg ml-1min (equivalent to 40% of the mouse LD10 AUC) for clinical studies. A phase I study to investigate the tolerance of a single i.v. infusion of tirapazamine (once every
3 weeks) was initiated with close pharmacokinetic monitoring. The starting dose (36 mg/m2) was based on toxicity data obtained in the mouse, rat and dog. Doses were escalated by increases in the volume and duration
of infusion. A retrospective analysis of the pharmacokinetic and toxicity data was then made to determine the utility of a
PGDE approach. The drug exhibited a steep dose-lethality relationship in mice (LD10 294 mg/m2, LD50 303 mg/m2). The major gross toxicities were body-weight loss (15–20%), pilo-erection and hypoactivity at all dose levels. Sporadic
ptosis and conjunctivitis were observed at doses of >300 mg/m2. The plasma elimination of tirapazamine fitted a monoexponential open model, with rapid elimination from the plasma (t
1/2=36±0.65 min) occuring at the LD10 dose of 294 mg/m2. A 10.3-fold increase in dose resulted in a 25.0-fold increase in AUC. Clinically, doses were escalated over the range of
36–450 mg/m2. Ototoxicity (tinnitus and reversible hearing loss) was dose-limiting at 450 mg/m2 and the MTD was 390 mg/m2 for this schedule. Pharmacokinetic analyses in patients revealed that the elimination of tirapazamine in patients was generally
bi-phasic, with low inter-patient variability being found in clearance. A 12.5-fold increase in dose resulted in a 19.0-fold
increase in AUC. There was good quantitative agreement in metabolite formation between mice and humans with respect to the
two- and four-electron bioreductive metabolites. AUC values recorded for tirapazamine at the MTD of 390 mg/m2 (range 1035–1611 μg ml-1min) were similar to the target AUC in mice. Importantly, these levels are consistent with the levels required for radiation-dose
enhancement and effective combination with cisplatin in mice. Given (a) the similarities in plasma pharmacokinetics and metabolism
observed at the target AUC/MTD in mice, rats, dogs and humans, (b) the similar degree of plasma protein binding seen between
species and (c) the relatively low inter-patient variability noted in drug clearance, a successful PGDE approach should have
been feasible. The results also indicate that potentially therapeutic levels of tirapazamine are achievable in patients at
tolerable doses.
Received: 27 May 1996 / Accepted: 30 September 1996 相似文献
53.
M. S. Vidyasagar Suresh Rao Donald J. Fernandes Ramanujam A. S. 《Indian journal of otolaryngology and head and neck surgery》1998,50(1):69-72
Primary Ewing’s sarcoma of the nasal bone has not been previously described. This case presented as a mass in the left ala
of the nose in a five year old female child. The clinical, radiological, microscopic features are described and a review of
literature is presented. The case was treated with neoadjuvant chemotherapy and local electron beam radiation therapy. The
child was free of disease when she reported for follow up in July 1997. Although wide excision is part of the treatment approach
in Ewing’s sarcoma, in sites where surgery is not suitable local radiotherapy and chemotherapy adequately controls primary
disease. 相似文献
54.
M. S. Vidyasagar Suresh Rao Donald J. Fernandes A. S. Ramanujam 《Indian journal of otolaryngology and head and neck surgery》1998,50(1):69-72
Primary Ewing’s sarcoma of the nasal bone has not been previously described. This case presented as a mass in the left ala of the nose in a five year old female child. The clinical, radiological, microscopic features are described and a review of literature is presented. The case was treated with neoadjuvant chemotherapy and local electron beam radiation therapy. The child was free of disease when she reported for follow up in July 1997. Although wide excision is part of the treatment approach in Ewing’s sarcoma, in sites where surgery is not suitable local radiotherapy and chemotherapy adequately controls primary disease. 相似文献
55.
56.
Jaimanti Naresh K. Panda Suresh Sharma Ashok K. Gupta S. B. S. Mann 《Indian journal of otolaryngology and head and neck surgery》2004,56(2):99-104
Conclusion Patients with stage I and II tumors had the best results with radical radiotherapy alone 5 years survival for patients with
stage I and stage II tumors was 90-95% and 75-85% respectively Patients with advanced stage III & IV disease were treated
Unoperable stage IV cancer patients had poor outcome and received only palliative treatment 相似文献
57.
The clinical relevance of steroid hormone receptor corepressors. 总被引:2,自引:0,他引:2
Rakesh Kumar Anupama E Gururaj Ratna K Vadlamudi Suresh K Rayala 《Clinical cancer research》2005,11(8):2822-2831
58.
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. 总被引:1,自引:0,他引:1
Cynthia X Ma Suresh Nair Sachdev Thomas Sumithra J Mandrekar Daniel A Nikcevich Kendrith M Rowland Tom R Fitch Harold E Windschitl Shauna L Hillman Steven E Schild James R Jett Coleman Obasaju Alex A Adjei 《Journal of clinical oncology》2005,23(25):5929-5937
PURPOSE: A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-na?ve patients with non-small-cell lung cancer. PATIENTS AND METHODS: Patients were randomly assigned to three schedules of pemetrexed 500 mg/m2 plus gemcitabine 1,250 mg/m2, separated by a 90-minute interval, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8. RESULTS: One hundred fifty-two eligible patients (schedule A, n = 59; schedule B, n = 31, and schedule C, n = 62) received a median of five (schedule A), two (schedule B), and four (schedule C) treatment cycles. Overall, 66% of patients experienced grade 3 or 4 neutropenia. Common grade 3 and 4 nonhematologic toxicities were dyspnea (11%), fatigue (16%), and transaminase elevation (9%). Schedule A seemed less toxic compared with schedule C (grade 3 or 4 events: 86% v 94%, respectively; P = .19; grade 4 events: 39% v 48%, respectively; P = .30). Schedule B was closed at interim analysis for inferior efficacy. Schedule A, with a confirmed response rate of 31% (95% CI, 20% to 45%), met the protocol-defined efficacy criteria, whereas schedule C, with a confirmed response rate of 16.1% (95% CI, 11% to 34%), did not. Median survival time and time to progression were 11.4 and 4.4 months, respectively, with no observable difference between the arms. CONCLUSION: Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated. 相似文献
59.
Jaimanti Bakshi Naresh K. Panda Suresh C. Sharma Ashok Gupta S. B. S. Mann 《Indian journal of otolaryngology and head and neck surgery》2005,57(2):103-107
Carcinoma of larynx is a common disease in North Indian population. It is seen commonly in smokers and alcoholics. It poses a serious health problem due to its tendency to cause airway obstruction and to make the patient aphonic if total larynxgectomy is done for curing this cancer. We conducted a retrospective analysis in 690 cases of carcinoma larynx presenting to Nehru Hospital, Postgraduate Institute of Medical Education and Research, Chandigarh. Various aspects of this disease like predisposing factors, patterns of spread, histological types, various treatment modalities, their complications and response of this disease to these therapeutic options were studied in detail. 相似文献
60.
Ameen Abdulla Salahudeen Manali I. Patel Paul Baas Walter J. Curran Jeffrey D. Bradley David R. Gandara Glenwood D. Goss Tony S. Mok Suresh S. Ramalingam Everett E. Vokes Shakun M. Malik Heather A. Wakelee 《Clinical lung cancer》2017,18(1):5-12
Survival rates of patients with either early and advanced stage non–small-cell lung cancer (NSCLC) have improved with newer systemic therapy and radiation techniques, including combination regimens, targeted therapies, and immunotherapies. The cancer cooperative groups have historically played a critical role in the advancement of NSCLC therapy. Annually, representatives from cooperative groups worldwide convene at the International Lung Cancer Congress (ILCC). In summer 2015, the ILCC reached its 16th anniversary. This article highlights the NSCLC studies presented by participating groups in 2015. 相似文献